Browse by People


Up a level
Export as [feed] RSS [feed] RSS 2.0 Short Author List
Number of items: 7.


Attard, Gerhardt, Murphy, Laura, Clarke, Noel W, Cross, William, Jones, Robert J ORCID: 0000-0001-5608-001X, Parker, Christopher C, Gillessen, Silke, Cook, Adrian, Brawley, Chris, Amos, Claire L
et al (show 38 more authors) (2022) Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. LANCET, 399 (10323). pp. 447-460.


James, Nicholas D, Clarke, Noel W, Cook, Adrian, Ali, Adnan, Hoyle, Alex P, Attard, Gerhardt, Brawley, Christopher D, Chowdhury, Simon, Cross, William R, Dearnaley, David P
et al (show 46 more authors) (2022) Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). INTERNATIONAL JOURNAL OF CANCER, 151 (3). pp. 422-434.


Clarke, Caroline S, Hunter, Rachael M, Gabrio, Andrea, Brawley, Christopher D, Ingleby, Fiona C, Dearnaley, David P, Matheson, David, Attard, Gerhardt, Rush, Hannah L, Jones, Rob J ORCID: 0000-0001-5608-001X
et al (show 12 more authors) (2022) Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data. PloS one, 17 (6). e0269192-e0269192.


James, Nicholas D, Ingleby, Fiona C, Clarke, Noel W, Amos, Claire L, Attard, Gerhardt, Brawley, Christopher D, Chowdhury, Simon, Cross, William, Dearnaley, David P, Gilbert, Duncan C
et al (show 37 more authors) (2022) Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial. JNCI cancer spectrum, 6 (4). pkac043-pkac043.


Wilson, Brooke E ORCID: 0000-0001-6557-7298, Armstrong, Andrew J ORCID: 0000-0001-7012-1754, de Bono, Johann ORCID: 0000-0002-2034-595X, Sternberg, Cora N ORCID: 0000-0003-3938-2627, Ryan, Charles J, Scher, Howard I, Smith, Matthew R, Rathkopf, Dana, Logothetis, Christopher J, Chi, Kim N ORCID: 0000-0002-3782-7226
et al (show 9 more authors) (2022) Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. European journal of cancer (Oxford, England : 1990), 170. pp. 296-304.


Gillessen, Silke, Bossi, Alberto, Davis, Ian D, de Bono, Johann ORCID: 0000-0002-2034-595X, Fizazi, Karim, James, Nicholas D ORCID: 0000-0002-7314-8204, Mottet, Nicolas, Shore, Neal, Small, Eric, Smith, Mathew
et al (show 108 more authors) (2023) Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. , Switzerland.


Willemse, Peter-Paul M, Davis, Niall F, Grivas, Nikolaos, Zattoni, Fabio, Lardas, Michael, Briers, Erik, Cumberbatch, Marcus G, De Santis, Maria, Dell'Oglio, Paolo, Donaldson, James F
et al (show 28 more authors) (2022) Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy. EUROPEAN UROLOGY, 81 (4). pp. 337-346.

This list was generated on Mon Mar 11 02:51:56 2024 GMT.